| Literature DB >> 34257742 |
Ying Yu1,2, Jie Gao1,3, Shasha Wang1,3, Heng Lv4, Liping Xiao4, Hengyuan Shi4, Xianjie Jia4.
Abstract
Aldehyde dehydrogenase 2 (ALDH2) polymorphisms are related to both stroke risk and alcohol consumption. However, the influence of ALDH2 polymorphisms and alcohol consumption on cognitive impairment after ischemic stroke remains unknown, as do the possible mechanisms. We enrolled 180 Han Chinese ischemic stroke patients from four community health centers in Bengbu, China. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA), and two different MoCA cutoff scores were used to define cognitive impairment in ischemic stroke patients. The ALDH2 genotypes were determined using polymerase chain reaction and direct sequencing. To assess the associations of ALDH2 polymorphisms and alcohol consumption with cognitive impairment after ischemic stroke, we performed binary logistic regression analysis with odds ratios. We revealed that individuals with the ALDH2 wild-type genotype were more likely to have high MoCA scores than those with the mutant and heterozygous types (p = 0.034). In addition, using two MoCA cutoff scores, the percentage of moderate to excessive alcohol consumption in the cognitive impairment group was higher than that in the nonimpairment group (p = 0.001). The levels of 4-hydroxy-2-nonenal (p = 0.001) and swallowing function (p = 0.001) were also higher in the cognitive impairment group than in the nonimpairment group. Moreover, after adjusting for other potential risk factors, ALDH2 polymorphisms and alcohol consumption had a significant synergistic effect on cognitive impairment (p = 0.022). Specifically, the ALDH2∗2 mutant allele and higher alcohol consumption were associated with cognitive impairment and swallowing ability after ischemic stroke. Targeting ALDH2 may be a useful biomarker for cognitive rehabilitation following ischemic stroke.Entities:
Year: 2021 PMID: 34257742 PMCID: PMC8253650 DOI: 10.1155/2021/6696806
Source DB: PubMed Journal: Behav Neurol ISSN: 0953-4180 Impact factor: 3.342
Figure 1Flowchart of the participant selection process.
Demographics of the study participants.
| Characteristics | ALDH2 genotypes |
|
| |
|---|---|---|---|---|
| ∗1/∗1 ( | ∗1/∗2 + ∗2/∗2 ( | |||
| Age (years) | 67.92 ± 8.02 | 69.88 ± 9.53 | 1.490 | 0.138 |
| Males, | 38 (43.7%) | 49 (52.7%) | 8.536 | 0.003 |
| Education | 7.013 | 0.071 | ||
| <6 years | 18 (20.7%) | 22 (23.7%) | ||
| 6-9 years | 27 (31.0%) | 19 (20.4%) | ||
| 9-12 years | 21 (24.1%) | 37 (39.8%) | ||
| >12 years | 21 (24.1%) | 15 (16.1%) | ||
| Alcohol consumption | 12.464 | 0.006 | ||
| Nondrinkers | 12.6% | 21.5% | ||
| Light drinkers | 8.0% | 22.6% | ||
| Moderate drinkers | 36.8% | 30.1% | ||
| Excessive drinkers | 42.5% | 25.8% | ||
Continuous variables are expressed as the mean ± standard deviation when normally distributed, and categorical variables are expressed as percentages.
Baseline characteristics of ischemic stroke patients with different ALDH2 genotypes.
| Characteristics | ALDH2 genotypes |
|
| |
|---|---|---|---|---|
| ∗1/∗1 ( | ∗1/∗2 + ∗2/∗2 ( | |||
| BMI (kg/m2) | 24.46 ± 2.91 | 25.22 ± 2.67 | 1.821 | 0.070 |
| SBP (mmHg) | 137.25 ± 20.10 | 142.65 ± 24.83 | 1.595 | 0.113 |
| DBP (mmHg) | 81.95 ± 9.24 | 82.09 ± 8.84 | 0.098 | 0.922 |
| FPG (mmol/L) | 7.31 ± 1.91 | 7.58 ± 1.98 | 0.911 | 0.363 |
| TC (mmol/L) | 6.16 ± 1.94 | 5.62 ± 1.40 | 2.106 | 0.037 |
| TG (mmol/L) | 2.13 ± 0.65 | 1.50 ± 0.65 | 1.252 | 0.214 |
| HDL-C (mmol/L) | 1.18 ± 0.37 | 1.15 ± 0.32 | 0.583 | 0.561 |
| LDL-C (mmol/L) | 2.51 ± 0.96 | 2.54 ± 0.75 | 0.234 | 0.815 |
| 4-HNE (ng/mL) | 12.18 ± 1.94 | 13.42 ± 2.11 | 4.096 | 0.001 |
Continuous variables are expressed as the mean ± standard deviation when normally distributed, and categorical variables are expressed as percentages. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; FPG: fasting plasma glucose; TC: total cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; 4-HNE: 4-hydroxy-trans-2-nonenal.
Figure 2Comparison of Montreal Cognitive Assessment (MoCA) scores of ischemic stroke patients grouped by ALDH2 genotype.
Comparison of alcohol consumption between the cognitive impairment and nonimpairment groups according to two different Montreal Cognitive Assessment (MoCA) cutoff scores.
| Alcohol consumption | Method 1 | Method 2 | ||
|---|---|---|---|---|
| Impairment | Nonimpairment | Impairment | Nonimpairment | |
| Nondrinkers | 21 (13.4%) | 10 (43.5%) | 12 (9.9%) | 19 (32.2%) |
| Light drinkers | 24 (15.3%) | 4 (17.4%) | 18 (14.9%) | 10 (16.9%) |
| Moderate drinkers | 52 (33.1%) | 8 (34.8%) | 44 (36.4%) | 16 (27.1%) |
| Excessive drinkers | 60 (38.2%) | 1 (4.3%) | 47 (38.8%) | 14 (23.7%) |
| Chi square | 17.419 | 15.238 | ||
|
| 0.001 | 0.002 | ||
Method 1: MoCA cutoff score of 26. Method 2: MoCA cutoff score of 23.
Figure 3Comparison of 4-hydroxy-trans-2-nonenal (4-HNE) levels between the cognitive impairment and nonimpairment groups according to two different Montreal Cognitive Assessment (MoCA) cutoff scores: (a) score of 26; (b) score of 23.
Comparison of swallowing function between the cognitive impairment and nonimpairment groups according to two different MoCA cutoff scores.
| Swallowing | Method 1 |
| Method 2 |
| ||
|---|---|---|---|---|---|---|
| Impairment | Nonimpairment | Impairment | Nonimpairment | |||
| Level I | 9 (5.7%) | 23 (100.0%) | 0.001 | 0 (0.0%) | 32 (54.2%) | 0.001 |
| Level II | 44 (28.0%) | 0 (0.0%) | 17 (14.0%) | 27 (45.8%) | ||
| Level III | 53 (33.8%) | 0 (0.0%) | 53 (43.8%) | 0 (0.0%) | ||
| Level IV | 29 (18.5%) | 0 (0.0%) | 29 (24.0%) | 0 (0.0%) | ||
| Level V | 22 (14.0%) | 0 (0.0%) | 22 (18.2%) | 0 (0.0%) | ||
Adjusted odds ratios (95% confidence intervals)a for the separate effects of ALDH2 polymorphism and alcohol consumption on cognitive impairment in ischemic stroke patients.
| Method 1 | Method 2 | |
|---|---|---|
| ALDH2 genotypes | ||
| ∗1/∗1 | Ref | Ref |
| ∗1/∗2 + ∗2/∗2 | 3.29 (1.03-10.50)∗ | 2.65 (1.19-5.92)∗ |
| Alcohol consumption | ||
| Nondrinkers | Ref | Ref |
| Light drinkers | 0.59 (0.16-0.89)# | 0.68 (0.33-0.89)# |
| Moderate drinkers | 0.77 (0.21-1.06) | 1.08 (0.83-2.19) |
| Excessive drinkers | 1.22 (1.16-1.49)# | 1.78 (1.03-2.15)# |
aModels were adjusted for age, gender, and education. ∗p < 0.05 vs. ALDH2 wild-type genotype group (ALDH2∗1/∗1). #p < 0.05 vs. nondrinkers.
Multivariate odds ratios (95% confidence intervals)a for alcohol consumption on cognitive impairment in stroke patients, stratified by ALDH2 polymorphism.
| ALDH2 genotypes | Alcohol consumption | Method 1 | Method 2 |
|---|---|---|---|
| ∗1/∗1 | Nondrinkers | Ref | Ref |
| Light drinkers | 1.75 (0.20-15.19) | 0.45 (0.05-3.91) | |
| Moderate drinkers | 2.97 (0.60-14.68) | 2.43 (0.54-11.02) | |
| Excessive drinkers | 7.75 (1.03-113.78)∗ | 3.93 (0.84-18.44) | |
|
| |||
| ∗1/∗2 | Nondrinkers | Ref | Ref |
| Light drinkers | 15.99 (0.96-266.02) | 13.74 (1.96-96.51)# | |
| Moderate drinkers | 10.95 (1.04-114.88)# | 22.36 (3.69-135.54)# | |
| Excessive drinkers | — | 20.93 (2.77-158.45)# | |
|
| |||
| ∗2/∗2 | Nondrinkers | — | — |
| Light drinkers | — | — | |
| Moderate drinkers | — | — | |
| Excessive drinkers | — | — | |
aModels were adjusted for age, gender, education, and subtype. ∗p < 0.05 vs. nondrinkers with ALDH2 wild-type genotype (ALDH2∗1/∗1). #p < 0.05 vs. nondrinkers with ALDH2 mutant genotype (ALDH2∗1/∗2).